Pilot study of fludarabine (F), cyclophosphamide (C), and amifostine (A) (FCA) in patients with chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Keating, AR [1 ]
O'Brien, SM [1 ]
Cortes, JE [1 ]
Thomas, D [1 ]
Koller, C [1 ]
Beran, M [1 ]
Kantarjian, HM [1 ]
Keating, MJ [1 ]
Giles, FJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1401
引用
收藏
页码：313A / 313A
页数：1
相关论文
共 50 条
  • [41] An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia
    Montillo, Marco
    Tedeschi, Alessandra
    Petrizzi, Valeria Belsito
    Ricci, Francesca
    Crugnola, Monica
    Spriano, Mauro
    Spedini, Pierangelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    Vismara, Eleonora
    De Blasio, Angelo
    Zaccaria, Alfonso
    Morra, Enrica
    BLOOD, 2011, 118 (15) : 4079 - 4085
  • [42] Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
    Kutsch, Nadine
    Fink, Anna Maria
    Federhen, Anno
    Giza, Adam
    Robrecht, Sandra
    Stumpf, Janina
    Stoltefuss, Andrea
    Vehling-Kaiser, Ursula
    Koenigsmann, Michael
    Tausch, Eugen
    Schneider, Christof
    Stilgenbauer, Stephan
    Illmer, Thomas
    Schlag, Rudolf
    Doerfel, Steffen
    Gaska, Tobias
    Kiehl, Michael G.
    Fischer, Kirsten
    Eichhorst, Barbara
    Hallek, Michael
    BLOOD, 2022, 140 : 9879 - 9881
  • [43] GENETIC DETERMINANTS OF FLUDARABINE-RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Messina, M.
    Del Giudice, I.
    Rossi, D.
    Chiaretti, S.
    Rasi, S.
    Spina, V.
    Khiabanian, H.
    Holmes, A.
    Marinelli, M.
    Fabbri, G.
    Rossi, A.
    Guarini, A.
    Pasqualucci, L.
    Rabadan, R.
    Dalla-Favera, R.
    Gaidano, G.
    Foa, R.
    HAEMATOLOGICA, 2013, 98 : 239 - 239
  • [44] The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen
    Panovska, Anna
    Lysak, Daniel
    Smolej, Lukas
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    BLOOD, 2012, 120 (21)
  • [45] The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab
    Panovska, Anna
    Smolej, Lukas
    Lysak, Daniel
    Brychtova, Yvona
    Simkovic, Martin
    Motyckova, Monika
    Vodarek, Pavel
    Lindtnerova, Michaela
    Trbusek, Martin
    Malcikova, Jitka
    Pospisilova, Sarka
    Mayer, Jiri
    Doubek, Michael
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (06) : 479 - 485
  • [46] Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia (CLL).
    Lamanna, N
    Weiss, MA
    Maslak, PG
    Gencarelli, AN
    Scheinberg, DA
    Horgan, D
    BLOOD, 2003, 102 (11) : 440A - 440A
  • [47] Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).
    Parikh, S. A.
    Wierda, W. G.
    Badoux, X.
    O'Brien, S. M.
    Ferrajoli, A.
    Faderl, S.
    Burger, J. A.
    Lerner, S.
    Kantarjian, H.
    Keating, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)
    Douglas, P.
    Lee, R.
    Worthington, K.
    Mistry, B.
    VALUE IN HEALTH, 2011, 14 (03) : A160 - A160
  • [49] Extended follow-up of a chemo-immunotherapy regimen FCR (Fludarabine, F; cyclophosphamide, C; and rituximab, R) as initial therapy for chronic lymphocytic leukemia (CLL).
    Keating, MJ
    O'Brien, S
    Albitar, M
    Lerner, S
    Wierda, W
    Kantarijan, H
    BLOOD, 2005, 106 (11) : 599A - 599A
  • [50] Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL).
    Keating, MJ
    O'Brien, S
    Lerner, S
    Giles, F
    Andreeff, M
    Cortes, J
    Albitar, M
    Kantarjian, H
    BLOOD, 2000, 96 (11) : 514A - 514A
12345